Digest Network Come funziona
Network
/
Società
Ge
Non verificato

Genentech

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

67 comunicati stampa

Guarda tutti i comunicati
20/01/2026
Biotecnologia
Industria
Salute
Farmaceutica
Genentech More than Doubles Investment in Holly Springs, North Carolina Manufacturing Facility
Fonte
Genentech
Emittente
Business Wire
1.00
0
22/12/2025
Industria
Salute
Igiene alimentare
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma
Fonte
Genentech
Emittente
Business Wire
1.00
0
19/12/2025
Mercato del lavoro
Industria
Politica Interna
Salute
Farmaceutica
Biotecnologia
Genentech Announces Agreement With U.S. Government
Fonte
Genentech
Emittente
Business Wire
1.00
0
10/12/2025
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Genentech’s Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-positive Early-Stage Breast Cancer
Fonte
Genentech
Emittente
Business Wire
1.00
0
08/12/2025
Eventi
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Genentech Presents Lunsumio Data Showing Potential Across Earlier Treatment Lines in Indolent and Aggressive Lymphomas
Fonte
Genentech
Emittente
Business Wire
1.00
0
18/11/2025
Industria
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Genentech’s Giredestrant Becomes the First Oral SERD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer
Fonte
Genentech
Emittente
Business Wire
1.00
0
10/11/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Industria
Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis
Fonte
Genentech
Emittente
Business Wire
1.00
0
03/11/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Eventi
Fiere
Industria
Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025
Fonte
Genentech
Emittente
Business Wire
1.00
0
03/11/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Industria
Positive Phase III Data for Genentech’s Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus
Fonte
Genentech
Emittente
Business Wire
1.00
0
28/10/2025
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Positive Phase III Results for Genentech’s Gazyva in Children and Young Adults With Idiopathic Nephrotic Syndrome
Fonte
Genentech
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0